Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 17, Issue 7, 2015, Pages 659-664

  Heise, T ^a   Nosek, L ^a   Klein, O ^a   Coester, H ^a   Svendsen, A L ^b   Haahr, H ^b  

^a Profil   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Dose response relationship; Pharmacodynamics; Type 1 diabetes

Indexed keywords

GLUCOSE; INSULIN ASPART; INSULIN ASPART PLUS INSULIN DEGLUDEC; ANTIDIABETIC AGENT; BIPHASIC INSULIN; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; INSULIN DEGLUDEC, INSULIN ASPART DRUG COMBINATION; LONG ACTING INSULIN;

ADULT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION RATE; HEADACHE; HUMAN; HYPOGLYCEMIA; INFUSION RATE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 1; DRUG COMBINATION; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AREA UNDER CURVE; BIPHASIC INSULINS; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84931955774     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12463     Document Type: Article

References (22)

1. Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab 2011; 13: 677-684.
2. Garber AJ. Insulin intensification strategies in type 2 diabetes: when one injection is no longer sufficient. Diabetes Obes Metab 2009; 11: 14-18.
3. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 45-52.
4. Riddle M, Rosenstock J, Vlajnic A, Gao L. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes Metab 2014; 16: 396-402.
5. Ryzodeg EPAR - Product Information. Novo Nordisk A/S. 6 February 2014. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002499/WC500139011.pdf. Accessed 22 August 2014.
6. Heise T, Nosek L, Roepstorff C, Chenji S, Klein O, Haahr H. Distinct prandial and basal glucose-lowering effects of insulin degludec/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes mellitus. Diabetes Ther 2014; 5: 255-265.
7. Kurtzhals P, Heise T, Strauss H. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologica 2011; 54: S426.
8. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 2014; 53: 787-800.
9. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14: 859-864.
10. Heise T, Nosek L, Hermanski L, Bottcher SG, Haahr H. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. J Clin Endocrinol Metab 2014.
11. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard D, Wahlund P, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29: 2104-2114.
12. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(Suppl. 1): S62-69.
13. Havelund S, Ribel U, Hubálek F, Hoeg-Jensen T, Wahlund PO, Jonassen I. Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart. Pharm Res 2015; DOI: 10.1007/s11095-014-1614-x [Epub ahead of print].
14. Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA. The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin. Diabetes Care 2012; 35: 690-692.
15. Heise T, Eckers U, Kanc K, Nielsen JN, Nosek L. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study. Diabetes Technol Ther 2008; 10: 479-485.
16. Hirao K, Maeda H, Urata S etal. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan. Clin Ther 2007; 29: 927-934.
17. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997; 20: 1612-1614.
18. Holman RR, Farmer AJ, Davies MJ etal. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-1747.
19. Inzucchi S, Bergenstal R, Buse J etal. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
20. Vaag A, Christiansen J, Niskanen L, Rasmussen S, Johansen T, Fulcher G. Lower rates of overall, nocturnal and severe hypoglycaemia during maintenance treatment with IDegAsp vs biphasic insulin aspart 30 in patients with type 2 diabetes mellitus: a meta-analysis. Diabetologica 2013; 56: S83.
21. Christiansen J, Chow F, Choi D, Taneda S, Hirao K. Superior FPG control and less nocturnal hypoglycaemia with IDegAsp vs BIAsp 30 in Asian subjects poorly controlled on basal or pre/self-mixed insulin: randomised phase 3 trial. Diabetologia 2013; 56: S420.
22. Fulcher GR, Christiansen JS, Bantwal G etal. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care 2014; 37: 2084-2090.